Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:29 August 2023

RESOLUTE: This study is assessing the benefit of using a type of local ablative therapy (which could include surgery or radiation therapy) on top of standard of care treatment for people with colorectal cancerRandomised Phase II Trial to Evaluate Progression-Free Survival in Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

Eligible participants will be randomly allocated to either the local ablative therapy (LAT) arm, or the control arm. In the LAT arm, participants will receive metastasis-directed LAT such as radiation therapy or thermal ablation following initial standard first-line systemic treatment. In the control arm, participants will receive continued first-line systemic treatment alone. Those receiving LAT will return to systemic treatment 16 weeks post-randomisation.

Age

People 18+

Phase

Not applicable

Trial Acronym

RESOLUTE

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

ACTRN12621001198819
NC284

Scientific Title

Randomised Phase II Trial to Evaluate Progression-Free Survival in Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

Share with email